Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2017 Summary Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis. Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 2, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Small Cell Lung Cancer, Solid Tumor, Leukemias, Squamous Cell Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Nasopharyngeal Cancer, Neuroblastoma, Ovarian Cancer, Pancreatic Cancer and Peripheral T-Cell Lymphomas (PTCL). The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H1 2017, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)targeted therapeutics and enlists all their major and minor projects - The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development Boehringer Ingelheim GmbH Cyclacel Pharmaceuticals Inc F. Hoffmann-La Roche Ltd Onconova Therapeutics Inc Takeda Pharmaceutical Company Ltd Trovagene Inc Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles CYC-140 - Drug Profile Product Description Mechanism Of Action R&D Progress LS-008 - Drug Profile Product Description Mechanism Of Action R&D Progress PCM-075 - Drug Profile Product Description Mechanism Of Action R&D Progress rigosertib sodium - Drug Profile Product Description Mechanism Of Action R&D Progress RO-5203280 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit PLK1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PLK1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PLK1 for Squamous Cell Carcinoma - Drug Profile Product Description Mechanism Of Action R&D Progress volasertib trihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones Featured News & Press Releases May 25, 2017: Phase 1 Safety Study Supports Planned Development of PCM-075 in AML May 22, 2017: Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association May 18, 2017: Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting May 01, 2017: Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes Apr 04, 2017: Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 Dec 06, 2016: Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting Dec 05, 2016: Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting Dec 01, 2016: Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia Nov 04, 2016: Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting Oct 10, 2016: Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City Sep 26, 2016: Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination Jul 19, 2016: Onconova Announces Enrollment of First Patient in Japan by SymBio Jun 13, 2016: Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting Jun 06, 2016: Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting Jun 02, 2016: Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Boehringer Ingelheim GmbH, H1 2017 Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Onconova Therapeutics Inc, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Pipeline by Trovagene Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
